Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
12/04/2019
Trade Name:
Latuda
Generic Name or Proper Name (*):
lurasidone hydrochloride
Indications Studied:
Postmarketing study
Label Changes Summary:
*In a long-term, open-label study that enrolled pediatric patients age 6 to 17 years with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. *In this trial, the mean increase in height from open-label baseline to Week 104 was 4.94 cm. The mean change in height z-score indicates a minimal deviation from the normal growth curve. *Postmarketing study.
PREA(P):
P
Sponsor:
Sunovion Pharmaceuticals, Inc.
NNPS:
FALSE
Therapeutic Category:
Antipsychotic
-
-